Combination chemotherapy with cisplatin-vinblastine in malignant mesothelioma

Απλή σελίδα τεκμηρίου
dc.contributor.authorTsavaris, N.en
dc.contributor.authorMylonakis, N.en
dc.contributor.authorKarvounis, N.en
dc.contributor.authorBacoyiannis, C.en
dc.contributor.authorBriasoulis, E.en
dc.contributor.authorSkarlos, D.en
dc.contributor.authorPavlidis, N.en
dc.contributor.authorStamatelos, G.en
dc.contributor.authorKosmidis, P.en
dc.date.accessioned2015-11-24T19:29:43Z
dc.date.available2015-11-24T19:29:43Z
dc.identifier.issn0169-5002-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/22992
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic useen
dc.subjectCisplatin/administration & dosageen
dc.subjectDrug Administration Scheduleen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectMaleen
dc.subjectMesothelioma/*drug therapyen
dc.subjectMiddle Ageden
dc.subjectPeritoneal Neoplasms/*drug therapyen
dc.subjectPleural Neoplasms/*drug therapyen
dc.subjectVinblastine/administration & dosageen
dc.titleCombination chemotherapy with cisplatin-vinblastine in malignant mesotheliomaen
heal.abstractFrom June 1985 to March 1993, 20 consecutive patients with histologically proven malignant mesothelioma were treated with cisplatin 100 mg/m2 i.v. infusion on day 1 and vinblastine 6 mg/m2 i.v. on day 1 and 8. Treatment was repeated every 4 weeks until progression. All patients were evaluated clinically and by CT-scan and were staged (Stage IV), according to Butchard's criteria, on entry to the study. None had prior surgical excision. Eighty-one chemotherapy cycles were administered to 20 patients. One complete response, four partial responses, nine stable diseases and six progressions were noted. One partial responder entered complete response following an operation. Toxicity was acceptable and no treatment-related deaths occurred. The median survival for responders was 19.3 months; for patients with stable disease 15.7 months and for non-responders, 5.2 months. The mean duration of response was 13 months. We conclude that for this small group of patients, the combination cisplatin-vinblastine is effective, with acceptable toxicity in malignant mesothelioma. Further study with a larger number of patients is necessary.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/7812707-
heal.identifier.secondaryhttp://ac.els-cdn.com/0169500294905509/1-s2.0-0169500294905509-main.pdf?_tid=801cad65798685357aebf82534bcfdb5&acdnat=1333703823_249ac9ad1bdc666df08647c33b55f98c-
heal.journalNameLung Canceren
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate1994-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ